Can the SMART Study Data Be Used to Assess Risk Factors for Renal Disease?

  1. Samir K. Gupta, MD, MS
  1. From Indiana University School of Medicine, Indianapolis, IN 46202.

    TO THE EDITOR:

    In the recent analysis by the SMART (Strategies for Management of Anti-Retroviral Therapy) Study Group (1), resumption of continuous antiretroviral therapy after structured treatment interruption did not fully abrogate the increased risk for serious adverse events and death associated with initial assignment to the drug conservation group of the trial. This …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med February 17, 2009 vol. 150 no. 4 282
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues